

Animesh D Pardanani

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6742541/animesh-d-pardanani-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

347
papers

11,935
citations

51
h-index

106
g-index

354
ext. papers

13,968
ext. citations

4.8
avg, IF

6.51
L-index

#	Paper	IF	Citations
347	Midostaurin therapy for indolent and smoldering systemic mastocytosis: retrospective review of Mayo Clinic experience.. <i>American Journal of Hematology</i> , 2022 ,	7.1	0
346	Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients.. <i>Blood Cancer Journal</i> , 2022 , 12, 26	7	1
345	-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity.. <i>Haematologica</i> , 2022 ,	6.6	1
344	Erythrocytosis associated with <i>TET2</i> , <i>DNMT3A</i> , or mutations: The Mayo Clinic experience.. <i>Haematologica</i> , 2022 ,	6.6	1
343	Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases.. <i>American Journal of Hematology</i> , 2022 ,	7.1	2
342	Real-world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts.. <i>American Journal of Hematology</i> , 2022 ,	7.1	0
341	Cytogenetic abnormalities in essential thrombocythemia: Clinical and molecular correlates and prognostic relevance in 809 informative cases.. <i>Blood Cancer Journal</i> , 2022 , 12, 44	7	1
340	Lymphocytopenia predicts shortened survival in myelodysplastic syndrome with ring sideroblasts (MDS-RS) but not in MDS/MPN-RS-T.. <i>American Journal of Hematology</i> , 2021 ,	7.1	2
339	Cladribine therapy for advanced and indolent systemic mastocytosis: Mayo Clinic experience in 42 consecutive cases. <i>British Journal of Haematology</i> , 2021 ,	4.5	3
338	High-Oxygen-Affinity Hemoglobinopathy-Associated Erythrocytosis: Clinical Outcomes and Impact of Therapy in 41 Cases. <i>Blood</i> , 2021 , 138, 1492-1492	2.2	
337	Anthracycline Choices for Induction Chemotherapy Among 797 Consecutive Adult Patients with Acute Myeloid Leukemia: Daunorubicin-60 Vs Idarubicin-12 Vs Daunorubicin-90. <i>Blood</i> , 2021 , 138, 1267-1267	2.2	
336	A Globally Applicable "Triple AAA" Risk Model for Essential Thrombocythemia Based on Age, Absolute Neutrophil Count, and Absolute Lymphocyte Count. <i>Blood</i> , 2021 , 138, 238-238	2.2	0
335	Deciphering the Individual Contribution of Absolute Neutrophil, Lymphocyte and Monocyte Counts to Thrombosis Risk in Patients with Myeloproliferative Neoplasms. <i>Blood</i> , 2021 , 138, 3651-3651	2.2	1
334	Cladribine Therapy for Advanced and Indolent Systemic Mastocytosis: Mayo Clinic Experience in 42 Consecutive Cases. <i>Blood</i> , 2021 , 138, 3657-3657	2.2	0
333	Acute Myeloid Leukemia in the Context of Previous History of Cancer with or without Exposure to Chemotherapy or Radiotherapy. <i>Blood</i> , 2021 , 138, 3368-3368	2.2	0
332	The 1.5 Million Platelet Count Threshold in Essential Thrombocythemia: Phenotype and Genotype Correlates and Relevance to Vascular Events. <i>Blood</i> , 2021 , 138, 3630-3630	2.2	
331	Deciphering the individual contribution of absolute neutrophil and monocyte counts to thrombosis risk in polycythemia vera and essential thrombocythemia. <i>American Journal of Hematology</i> , 2021 , 97, E35	7.1	2

330	A population-based study of outcomes in polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the United States from 2001 to 2015: Comparison with data from a Mayo Clinic single institutional series. <i>American Journal of Hematology</i> , 2021 , 96, E464-E468	7.1	0
329	High-oxygen-affinity hemoglobinopathy-associated erythrocytosis: Clinical outcomes and impact of therapy in 41 cases. <i>American Journal of Hematology</i> , 2021 , 96, 1647-1654	7.1	3
328	Acute myeloid leukemia after age 70 years: A retrospective comparison of survival following treatment with intensive versus HMA + venetoclax chemotherapy. <i>American Journal of Hematology</i> , 2021 , 96, E108-E111	7.1	3
327	Mayo Clinic experience with 1123 adults with acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2021 , 11, 46	7	1
326	CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes. <i>Blood Cancer Journal</i> , 2021 , 11, 54	7	1
325	Extreme thrombocytosis in low-risk essential thrombocythemia: Retrospective review of vascular events and treatment strategies. <i>American Journal of Hematology</i> , 2021 , 96, E182-E184	7.1	6
324	Mutations and thrombosis in essential thrombocythemia. <i>Blood Cancer Journal</i> , 2021 , 11, 77	7	8
323	JAK2 unmutated erythrocytosis: current diagnostic approach and therapeutic views. <i>Leukemia</i> , 2021 , 35, 2166-2181	10.7	7
322	Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases. <i>American Journal of Hematology</i> , 2021 , 96, 781-789	7.1	17
321	Clinical and biological characteristics and prognostic impact of somatic GATA2 mutations in myeloid malignancies: a single institution experience. <i>Blood Cancer Journal</i> , 2021 , 11, 122	7	0
320	Pregnancy in patients with myelofibrosis: Mayo-Florence series of 24 pregnancies in 16 women. <i>British Journal of Haematology</i> , 2021 , 195, 133-137	4.5	1
319	Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis. <i>British Journal of Haematology</i> , 2021 , 195, 244-248	4.5	7
318	The Impact of Obesity on the Outcomes of Adult Patients with Acute Lymphoblastic Leukemia - A Single Center Retrospective Study. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2021 , 11, 1-9	2.6	2
317	Young platelet millionaires with essential thrombocythemia. <i>American Journal of Hematology</i> , 2021 , 96, E93-E95	7.1	5
316	Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management. <i>American Journal of Hematology</i> , 2021 , 96, 508-525	7.1	26
315	Single-agent cladribine as an effective front-line therapy for adults with Langerhans cell histiocytosis. <i>American Journal of Hematology</i> , 2021 , 96, E146-E150	7.1	7
314	Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation. <i>Blood Cancer Journal</i> , 2021 , 11, 49	7	11
313	De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases. <i>British Journal of Haematology</i> , 2021 , 195, 413-416	4.5	1

312	Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients. <i>American Journal of Hematology</i> , 2021 , 96, 1472-1480	7.1	2
311	81-Year-Old Man With Insomnia and Pruritus. <i>Mayo Clinic Proceedings</i> , 2020 , 95, e59-e64	6.4	
310	A population-based study of chronic neutrophilic leukemia in the United States. <i>Blood Cancer Journal</i> , 2020 , 10, 68	7	7
309	Clinical outcomes of adults with hemophagocytic lymphohistiocytosis treated with the HLH-04 protocol: a retrospective analysis. <i>Leukemia and Lymphoma</i> , 2020 , 61, 1592-1600	1.9	6
308	Erythrocytosis associated with cerebral hemangiomas and multiple venous anomalies. <i>American Journal of Hematology</i> , 2020 , 95, 1224	7.1	3
307	A population-based study of chronic eosinophilic leukemia-not otherwise specified in the United States. <i>American Journal of Hematology</i> , 2020 , 95, E257	7.1	2
306	Spectrum of abnormalities and clonal transformation in germline RUNX1 familial platelet disorder and a genomic comparative analysis with somatic RUNX1 mutations in MDS/MPN overlap neoplasms. <i>Leukemia</i> , 2020 , 34, 2519-2524	10.7	10
305	Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. <i>British Journal of Haematology</i> , 2020 , 189, 291-302	4.5	58
304	Phenotypic correlates and prognostic outcomes of TET2 mutations in myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: A comprehensive study of 504 adult patients. <i>American Journal of Hematology</i> , 2020 , 95, E86-E89	7.1	2
303	Pregnancy outcomes in myeloproliferative neoplasms: A Mayo Clinic report on 102 pregnancies. <i>American Journal of Hematology</i> , 2020 , 95, E114-E117	7.1	6
302	WHO defined chronic eosinophilic leukemia, not otherwise specified (CEL, NOS): A contemporary series from the Mayo Clinic. <i>American Journal of Hematology</i> , 2020 , 95, E172-E174	7.1	12
301	Spectrum of Hematological Malignancies in 130 Patients with Germline Predisposition Syndromes - Mayo Clinic Germline Predisposition Study. <i>Blood</i> , 2020 , 136, 34-35	2.2	
300	Clinical, Molecular, and Prognostic Comparisons between Clonal Cytopenias of Undetermined Significance and Lower-Risk Myelodysplastic Syndromes - a Study of 184 Molecularly Annotated Patients. <i>Blood</i> , 2020 , 136, 35-36	2.2	
299	A Population-Based Study of Chronic Myelomonocytic Leukemia in the United States from 2004-2015. <i>Blood</i> , 2020 , 136, 30-31	2.2	
298	Pre- Transplant Ferritin Predicts Overall Survival and Non-Relapse Mortality in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis. <i>Blood</i> , 2020 , 136, 19-20	2.2	
297	A Multicenter Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Poor-Risk Primary and Secondary Myelofibrosis. <i>Blood</i> , 2020 , 136, 39-40	2.2	6
296	Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 1248-1269	7.3	10
295	Clinical utility of fluorescence in situ hybridization-based diagnosis of BCR-ABL1 like (Philadelphia chromosome like) B-acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2020 , 95, E68-E72	7.1	2

294	Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients. <i>Leukemia</i> , 2020 , 34, 1407-1421	10.7	40
293	Prevalence and spectrum of T-cell lymphoproliferative disorders in patients with Hypereosinophilia: A reference laboratory experience. <i>Annals of Diagnostic Pathology</i> , 2020 , 44, 1514-1521	2.2	3
292	Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients. <i>American Journal of Hematology</i> , 2020 , 95, 1511-1521	7.1	28
291	Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model. <i>Blood Cancer Journal</i> , 2019 , 9, 12	7	28
290	Germline SH2B3 pathogenic variant associated with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. <i>American Journal of Hematology</i> , 2019 , 94, E231-E234	7.1	4
289	Cytogenetic clonal evolution in myeloproliferative neoplasms: contexts and prognostic impact among 648 patients with serial bone marrow biopsies. <i>Leukemia</i> , 2019 , 33, 2522-2553	10.7	1
288	World Health Organization class-independent risk categorization in mastocytosis. <i>Blood Cancer Journal</i> , 2019 , 9, 29	7	5
287	3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 599-610	6.4	50
286	Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients. <i>American Journal of Hematology</i> , 2019 , 94, 767-779	7.1	27
285	A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapy. <i>Blood Cancer Journal</i> , 2019 , 9, 11	7	8
284	Phenotypic heterogeneity associated with germline haploinsufficiency: a comprehensive kindred study. <i>Leukemia and Lymphoma</i> , 2019 , 60, 3282-3286	1.9	2
283	Etiologies of Extreme Thrombocytosis: A Contemporary Series. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 1542-1550	15.0	5
282	Spectrum of Abnormalities and Clonal Transformation in Germline RUNX1 Familial Platelet Disorder and a Comparative Analysis with Somatic RUNX1 Mutations in Myeloid Neoplasms. <i>Blood</i> , 2019 , 134, 3003-3003	2.2	1
281	Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis. <i>Blood</i> , 2019 , 134, 558-558	2.2	17
280	Response to Erythropoiesis Stimulating Agents in Patients with WHO-Defined Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T). <i>Blood</i> , 2019 , 134, 4182-4182	2.2	1
279	Phenotypic Correlates and Prognostic Outcomes of TET2 Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504 Patients. <i>Blood</i> , 2019 , 134, 3005-3005	2.2	
278	Functional Interrogation of Variants of Undetermined Significance of the Isocitrate Dehydrogenase 1 and 2 Genes in Myeloid Neoplasms. <i>Blood</i> , 2019 , 134, 1697-1697	2.2	
277	Acute Myeloid Leukemia with High Risk Features: Routine Central Nervous System Evaluation May be Beneficial. <i>Blood</i> , 2019 , 134, 3863-3863	2.2	

276	Clinical Categorization of Chronic Myelomonocytic Leukemia into Proliferative and Dysplastic Subtypes Correlates with Distinct Genomic, Transcriptomic and Epigenomic Signatures. <i>Blood</i> , 2019 , 134, 1710-1710	2.2	
275	Essential Thrombocythemia. <i>New England Journal of Medicine</i> , 2019 , 381, 2135-2144	59.2	50
274	Functional evaluation of isocitrate dehydrogenase 1 and 2 variants of unclear significance in chronic myeloid neoplasms. <i>Leukemia Research</i> , 2019 , 87, 106264	2.7	
273	Mutations and prognosis in myeloproliferative neoplasms. <i>Leukemia and Lymphoma</i> , 2019 , 60, 1112-1113	3.9	1
272	Calculator-free point-of-care prognostication in myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2019 , 94, E99-E101	7.1	
271	Determinants of long-term outcome in type 1 calreticulin-mutated myelofibrosis. <i>Leukemia</i> , 2019 , 33, 780-785	10.7	2
270	The germline JAK2 GGCC (46/1) haplotype and survival among 414 molecularly-annotated patients with primary myelofibrosis. <i>American Journal of Hematology</i> , 2019 , 94, 299-305	7.1	5
269	20+ Years and alive with primary myelofibrosis: Phenotypic signature of very long-lived patients. <i>American Journal of Hematology</i> , 2019 , 94, 286-290	7.1	3
268	Smoldering mastocytosis: Survival comparisons with indolent and aggressive mastocytosis. <i>American Journal of Hematology</i> , 2019 , 94, E1-E2	7.1	10
267	Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide. <i>American Journal of Hematology</i> , 2019 , 94, 5-9	7.1	3
266	Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management. <i>American Journal of Hematology</i> , 2019 , 94, 363-377	7.1	71
265	Pre-anthracycline echocardiogram rarely changes treatment strategy in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018 , 93, E144-E146	7.1	
264	U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions. <i>Leukemia</i> , 2018 , 32, 2274-2278	10.7	47
263	U2AF1 mutation variants in myelodysplastic syndromes and their clinical correlates. <i>American Journal of Hematology</i> , 2018 , 93, E146-E148	7.1	7
262	The impact of sex on disease phenotype and prognostic thresholds of anemia in myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2018 , 93, E164-E167	7.1	1
261	GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. <i>Leukemia</i> , 2018 , 32, 1631-1642	10.7	17
260	Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients. <i>Leukemia</i> , 2018 , 32, 1254-1258	10.7	26
259	Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. <i>Leukemia</i> , 2018 , 32, 1200-1210	10.7	68

258	Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts. <i>Blood Cancer Journal</i> , 2018 , 8, 18	7	13
257	Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients. <i>Leukemia</i> , 2018 , 32, 1189-1199	10.7	65
256	Mutations and prognosis in myelodysplastic syndromes: karyotype-adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk model. <i>American Journal of Hematology</i> , 2018 , 93, 691-697	7.1	34
255	Mayo CALR mutation type classification guide using alpha helix propensity. <i>American Journal of Hematology</i> , 2018 , 93, E128-E129	7.1	11
254	Normal karyotype in myelofibrosis: is prognostic integrity affected by the number of metaphases analyzed?. <i>Blood Cancer Journal</i> , 2018 , 8, 8	7	0
253	JAK2 exon 12 mutated polycythemia vera: Mayo-Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2V617F mutated disease. <i>American Journal of Hematology</i> , 2018 , 93, E93-E96	7.1	14
252	Monocytosis is a powerful and independent predictor of inferior survival in primary myelofibrosis. <i>British Journal of Haematology</i> , 2018 , 183, 835-838	4.5	23
251	A retrospective survey of exposure history to chemotherapy or radiotherapy in 940 consecutive patients with primary myelofibrosis. <i>American Journal of Hematology</i> , 2018 , 93, E103-E107	7.1	
250	Cytogenetic findings in WHO-defined polycythaemia vera and their prognostic relevance. <i>British Journal of Haematology</i> , 2018 , 182, 437-440	4.5	14
249	A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone. <i>Leukemia</i> , 2018 , 32, 1850-1856	10.7	19
248	Momelotinib therapy for myelofibrosis: a 7-year follow-up. <i>Blood Cancer Journal</i> , 2018 , 8, 29	7	27
247	Prefibrotic versus overtly fibrotic primary myelofibrosis: clinical, cytogenetic, molecular and prognostic comparisons. <i>British Journal of Haematology</i> , 2018 , 182, 594-597	4.5	18
246	Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosis. <i>Blood Cancer Journal</i> , 2018 , 8, 57	7	17
245	Myelofibrosis Treatment Algorithm 2018. <i>Blood Cancer Journal</i> , 2018 , 8, 72	7	22
244	A Test Utilization Approach to the Diagnostic Workup of Isolated Eosinophilia in Otherwise Morphologically Unremarkable Bone Marrow: A Single Institutional Experience. <i>American Journal of Clinical Pathology</i> , 2018 , 150, 421-431	1.9	6
243	Early thrombotic events and preemptive systemic anticoagulation following splenectomy for myelofibrosis. <i>American Journal of Hematology</i> , 2018 , 93, E235-E238	7.1	7
242	Mast cell activation syndrome: Importance of consensus criteria and call for research. <i>Journal of Allergy and Clinical Immunology</i> , 2018 , 142, 1008-1010	11.5	22
241	CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival. <i>Blood Cancer Journal</i> , 2018 , 8, 21	7	17

240	Cytogenetic abnormalities in systemic mastocytosis: WHO subcategory-specific incidence and prognostic impact among 348 informative cases. <i>American Journal of Hematology</i> , 2018 , 93, 1461-1466	7.1	17
239	How I treat myelofibrosis after failure of JAK inhibitors. <i>Blood</i> , 2018 , 132, 492-500	2.2	30
238	Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information. <i>Mayo Clinic Proceedings</i> , 2018 , 93, 1363-1374	6.4	14
237	Mutation-Enhanced International Prognostic Systems for Essential Thrombocythemia (MIPSS-ET) and Polycythemia Vera (MIPSS-PV). <i>Blood</i> , 2018 , 132, 578-578	2.2	5
236	20+ Years and Alive with Primary Myelofibrosis: Phenotypic Signature of Very Long-Lived Patients. <i>Blood</i> , 2018 , 132, 4301-4301	2.2	0
235	3,023 Mayo Clinic Patients with Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. <i>Blood</i> , 2018 , 132, 3035-3035	2.2	1
234	Mutations and Thrombosis in Essential Thrombocythemia and Polycythemia Vera: Mayo-Careggi Alliance Study. <i>Blood</i> , 2018 , 132, 3040-3040	2.2	1
233	Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis. <i>Blood</i> , 2018 , 132, 1773-1773	2.2	3
232	Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML). <i>Blood</i> , 2018 , 132, 1821-1821	2.2	9
231	Predictors of Spleen and Anemia Response to Specific Drugs in Primary Myelofibrosis. <i>Blood</i> , 2018 , 132, 4300-4300	2.2	
230	Safety and Tolerability of Lurbinectedin (PM01183) in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , 2018 , 132, 2722-2722	2.2	2
229	Serum Erythropoietin Levels in Essential Thrombocythemia: Phenotypic and Prognostic Correlates. <i>Blood</i> , 2018 , 132, 3034-3034	2.2	
228	The Clinical Utility of Pharmacogenomics Testing in Assessing Tyrosine Kinase Inhibitor Therapy, Intolerance and Responses in Patients with Chronic Myelogenous Leukemia. <i>Blood</i> , 2018 , 132, 5440-5440	2.2	1
227	The Germline JAK2 GGCC (46/1) Haplotype and Survival Among 414 Molecularly-Annotated Patients with Primary Myelofibrosis. <i>Blood</i> , 2018 , 132, 1761-1761	2.2	
226	Decreased Survival and Increased Rate of Fibrotic Progression in Essential Thrombocythemia Chronicled after the FDA Approval Date of Anagrelide. <i>Blood</i> , 2018 , 132, 4287-4287	2.2	
225	Clinical and Molecular Models of Prognostication in Mastocytosis: Analysis Based on 580 Consecutive Cases. <i>Blood</i> , 2018 , 132, 582-582	2.2	
224	Determinants of Long-Term Outcome in Type 1/like Calreticulin-Mutated Myelofibrosis. <i>Blood</i> , 2018 , 132, 1767-1767	2.2	
223	Indoleamine 2,3-Dioxygenase-1 Expressing Dendritic Cell Populations Are Associated with Tumor-Induced Immune Tolerance & Aggressive Disease Biology in Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2018 , 132, 4344-4344	2.2	

222	Cytogenetic Abnormalities in Systemic Mastocytosis: Who Subcategory-Specific Incidence and Prognostic Impact Among 348 Informative Cases. <i>Blood</i> , 2018 , 132, 3050-3050	2.2	
221	Myeloproliferative Neoplasms in Young Patients: The Mayo Clinic Experience with 361 Cases Age 40 Years or Younger. <i>Blood</i> , 2018 , 132, 3033-3033	2.2	
220	Cytogenetic Clonal Evolution in Myeloproliferative Neoplasms: Contexts and Prognostic Impact Among 650 Patients with Serial Bone Marrow Biopsies. <i>Blood</i> , 2018 , 132, 4291-4291	2.2	
219	MPL-Mutated Essential Thrombocythemia: A Morphologic Reappraisal. <i>Blood</i> , 2018 , 132, 3036-3036	2.2	
218	Clinical Correlates, Prognostic Impact and Survival Outcomes in Chronic Myelomonocytic Leukemia Patients with Myeloproliferative Neoplasm Associated-Driver Mutations. <i>Blood</i> , 2018 , 132, 3100-3100	2.2	
217	1,123 Consecutive Adults with Non-APL Acute Myeloid Leukemia: The Mayo Clinic Experience. <i>Blood</i> , 2018 , 132, 2689-2689	2.2	
216	Risk Factors for Leukemic Transformation Among 1,306 Patients with Primary Myelofibrosis: Mutations Predict Early Events. <i>Blood</i> , 2018 , 132, 3044-3044	2.2	
215	A Prospective Evaluation of Vitamin B1 (thiamine) Level in Myeloproliferative Neoplasms: Clinical Correlations and Impact of JAK2 Inhibitor Therapy. <i>Blood</i> , 2018 , 132, 1771-1771	2.2	
214	Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients. <i>American Journal of Hematology</i> , 2018 , 93, 348-355	7.1	54
213	Screening for ASXL1 and SRSF2 mutations is imperative for treatment decision-making in otherwise low or intermediate-1 risk patients with myelofibrosis. <i>British Journal of Haematology</i> , 2018 , 183, 678-681	4.5	10
212	Splanchnic vein thrombosis in patients with myeloproliferative neoplasms: The Mayo clinic experience with 84 consecutive cases. <i>American Journal of Hematology</i> , 2018 , 93, E61-E64	7.1	23
211	MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. <i>Journal of Clinical Oncology</i> , 2018 , 36, 310-318	2.2	224
210	MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1769-1770	2.2	123
209	MPL-mutated essential thrombocythemia: a morphologic reappraisal. <i>Blood Cancer Journal</i> , 2018 , 8, 1217		13
208	Serum erythropoietin levels in essential thrombocythemia: phenotypic and prognostic correlates. <i>Blood Cancer Journal</i> , 2018 , 8, 118	7	3
207	Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018 , 16, 1500-1537	7.3	23
206	Genetic predictors of response to specific drugs in primary myelofibrosis. <i>Blood Cancer Journal</i> , 2018 , 8, 120	7	0
205	A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and FLT3-ITD mutational status. <i>American Journal of Hematology</i> , 2018 , 93, E401-E404	7.1	2

204	Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms. <i>Blood Cancer Journal</i> , 2018 , 8, 82	7	14
203	Mutations and karyotype predict treatment response in myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2018 , 93, 1420-1426	7.1	18
202	Practice-relevant demarcation of systemic mastocytosis associated with another hematologic neoplasm. <i>American Journal of Hematology</i> , 2018 , 93, E383-E386	7.1	2
201	Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger. <i>American Journal of Hematology</i> , 2018 , 93, 1474-1484	7.1	31
200	Targeted next-generation sequencing in blast phase myeloproliferative neoplasms. <i>Blood Advances</i> , 2018 , 2, 370-380	7.8	55
199	Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models. <i>Blood Advances</i> , 2018 , 2, 2964-2972	7.8	40
198	Genotype-Phenotype Correlation of Hereditary Erythrocytosis Mutations, a single center experience. <i>American Journal of Hematology</i> , 2018 , 93, 1029	7.1	26
197	The prognostic relevance of serum lactate dehydrogenase and mild bone marrow reticulin fibrosis in essential thrombocythemia. <i>American Journal of Hematology</i> , 2017 , 92, 454-459	7.1	9
196	Monocytosis in polycythemia vera: Clinical and molecular correlates. <i>American Journal of Hematology</i> , 2017 , 92, 640-645	7.1	31
195	Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R. <i>American Journal of Hematology</i> , 2017 , 92, 1311-1317	7.1	50
194	Current treatment preferences in chronic myeloid leukemia: The Mayo Clinic Physicians' survey. <i>American Journal of Hematology</i> , 2017 , 92, E626-E627	7.1	1
193	Risk factors and a prognostic model for postsplenectomy survival in myelofibrosis. <i>American Journal of Hematology</i> , 2017 , 92, 1187-1192	7.1	17
192	Gender and survival in essential thrombocythemia: A two-center study of 1,494 patients. <i>American Journal of Hematology</i> , 2017 , 92, 1193-1197	7.1	18
191	The effect of arterial hypertension on thrombosis in low-risk polycythemia vera. <i>American Journal of Hematology</i> , 2017 , 92, E5-E6	7.1	32
190	Marked elevation of serum lactate dehydrogenase in primary myelofibrosis: clinical and prognostic correlates. <i>Blood Cancer Journal</i> , 2017 , 7, 657	7	5
189	Mutations and karyotype in myelodysplastic syndromes: TP53 clusters with monosomal karyotype, RUNX1 with trisomy 21, and SF3B1 with inv(3)(q21q26.2) and del(11q). <i>Blood Cancer Journal</i> , 2017 , 7, 658	7	13
188	Targeted deep sequencing in polycythemia vera and essential thrombocythemia. <i>Blood Advances</i> , 2016 , 1, 21-30	7.8	163
187	Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management. <i>American Journal of Hematology</i> , 2016 , 91, 1146-1159	7.1	73

186	Targeted next generation sequencing of PDGFRB rearranged myeloid neoplasms with monocytosis. <i>American Journal of Hematology</i> , 2016 , 91, E12-4	7.1	17
185	Momelotinib Therapy in Myelofibrosis: 6-Years Follow-up Data on Safety, Efficacy and the Impact of Mutations on Overall and Relapse-Free Survival. <i>Blood</i> , 2016 , 128, 1123-1123	2.2	4
184	Myeloid Sarcoma: The Mayo Clinic Experience of Ninety Six Case Series. <i>Blood</i> , 2016 , 128, 2798-2798	2.2	3
183	Marked Elevation of Serum Lactate Dehydrogenase (LDH) in Primary Myelofibrosis: Clinical and Prognostic Correlates. <i>Blood</i> , 2016 , 128, 3113-3113	2.2	2
182	Abnormal Karyotype and Prognosis in Polycythemia Vera: A Single Center Experience in 239 Informative Cases. <i>Blood</i> , 2016 , 128, 3115-3115	2.2	1
181	Results from Ongoing Phase 2 Trial of SL-401 in Patients with Advanced, High-Risk Myeloproliferative Neoplasms Including Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2016 , 128, 4245-4245	2.2	9
180	Prefibrotic Versus Overtly Fibrotic Primary Myelofibrosis: Clinical, Cytogenetic, Molecular and Prognostic Comparisons. <i>Blood</i> , 2016 , 128, 4247-4247	2.2	2
179	U2AF1 Mutation Variants and Their Phenotypic and Prognostic Relevance in Primary Myelofibrosis. <i>Blood</i> , 2016 , 128, 4248-4248	2.2	1
178	Monocytosis Is a Powerful and Independent Predictor of Shortened Overall and Leukemia-Free Survival in Primary Myelofibrosis. <i>Blood</i> , 2016 , 128, 4249-4249	2.2	2
177	Risk Factors for Arterial Versus Venous Thrombosis in Polycythemia Vera: Single Center Experience in 587 Patients. <i>Blood</i> , 2016 , 128, 948-948	2.2	1
176	Initial presentation of CNS-restricted acute lymphoblastic B cell leukaemia as peripheral polyneuropathy. <i>BMJ Case Reports</i> , 2016 , 2016, 10.1136/bcr-2016-214645	0.9	1
175	Prognostic Impact of Bone Marrow Fibrosis in Polycythemia Vera: Validation of the IWG-MRT Study and Additional Observations. <i>Blood</i> , 2016 , 128, 3129-3129	2.2	
174	Prognostic Relevance of Monocytopenia and Lymphocyte-to-Monocyte Ratio in Primary Myelodysplastic Syndromes. <i>Blood</i> , 2016 , 128, 1996-1996	2.2	
173	Monocytosis in Polycythemia Vera: Clinical and Molecular Correlates. <i>Blood</i> , 2016 , 128, 4259-4259	2.2	
172	Next-Generation Sequencing in Myelodysplastic Syndromes: Prognostic Interaction Between Adverse Mutations and IPSS-R. <i>Blood</i> , 2016 , 128, 1986-1986	2.2	
171	Subnormal Lymphocyte Count Predicts Inferior Survival in Myelodysplastic Syndromes: A Single Center Experience in 889 Patients. <i>Blood</i> , 2016 , 128, 5534-5534	2.2	0
170	Identification of Serum Lactate Dehydrogenase (LDH) As an Independent Prognostic Biomarker in Polycythemia Vera. <i>Blood</i> , 2016 , 128, 3111-3111	2.2	
169	The Prognostic Relevance of Serum Lactate Dehydrogenase and Mild Reticulin Fibrosis in Essential Thrombocythemia. <i>Blood</i> , 2016 , 128, 3120-3120	2.2	

168	Next generation sequencing of myeloid neoplasms with eosinophilia harboring the FIP1L1-PDGFR mutation. <i>American Journal of Hematology</i> , 2016 , 91, E10-1	7.1	17
167	Next-generation sequencing in systemic mastocytosis: Derivation of a mutation-augmented clinical prognostic model for survival. <i>American Journal of Hematology</i> , 2016 , 91, 888-93	7.1	47
166	Pruritus in primary myelofibrosis: management options in the era of JAK inhibitors. <i>Annals of Hematology</i> , 2016 , 95, 1185-9	3	10
165	ASXL1 and CBL mutations are independently predictive of inferior survival in advanced systemic mastocytosis. <i>British Journal of Haematology</i> , 2016 , 175, 534-536	4.5	19
164	Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia. <i>American Journal of Hematology</i> , 2016 , 91, 503-6	7.1	37
163	Concurrent activating KIT mutations in systemic mastocytosis. <i>British Journal of Haematology</i> , 2016 , 173, 153-6	4.5	11
162	Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2015 , 90, 250-62	7.1	64
161	Myeloproliferative Neoplasms: A Contemporary Review. <i>JAMA Oncology</i> , 2015 , 1, 97-105	13.4	195
160	Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial. <i>JAMA Oncology</i> , 2015 , 1, 643-51	13.4	242
159	Primary Myelodysplastic Syndromes: The Mayo Clinic Experience With 1000 Patients. <i>Mayo Clinic Proceedings</i> , 2015 , 90, 1623-38	6.4	10
158	Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis. <i>British Journal of Haematology</i> , 2015 , 169, 77-80	4.5	44
157	Morphologically occult systemic mastocytosis in bone marrow: clinicopathologic features and an algorithmic approach to diagnosis. <i>American Journal of Clinical Pathology</i> , 2015 , 144, 493-502	1.9	10
156	Acquired factor V deficiency in myeloproliferative neoplasms: a Mayo Clinic series of 33 patients. <i>British Journal of Haematology</i> , 2015 , 171, 875-9	4.5	3
155	ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia. <i>American Journal of Hematology</i> , 2015 , 90, 653-6	7.1	58
154	Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition. <i>Nature Medicine</i> , 2015 , 21, 1473-80	50.5	97
153	Driver Mutations and Prognosis in 502 Patients with Essential Thrombocythemia. <i>Blood</i> , 2015 , 126, 1599-1599	1	1
152	Spectrum of Mutations Associated with Hereditary Erythrocytosis. <i>Blood</i> , 2015 , 126, 2140-2140	2.2	1
151	Driver Mutations and Prognosis in 1118 Patients with Primary Myelofibrosis. <i>Blood</i> , 2015 , 126, 2801-2801	1.2	1

150	Peripheral Blood JAK2V617F Quantitative Assessment in Clinical Practice: Correlations Between Allele Burden and Clinical Phenotype. <i>Blood</i> , 2015 , 126, 2819-2819	2.2	1
149	A 27-Gene NGS Panel in Primary Myelofibrosis Identifies ASXL1, CBL, RUNX1 and SRSF2 Mutations As Being Unfavorable and Absence of Any Non-Driver Mutation As Being Favorable to Survival. <i>Blood</i> , 2015 , 126, 350-350	2.2	1
148	Targeted Next-Generation Sequencing in Polycythemia Vera and Essential Thrombocythemia. <i>Blood</i> , 2015 , 126, 354-354	2.2	9
147	Busulfan for the Treatment of Myeloproliferative Neoplasms: The Mayo Clinic Experience. <i>Blood</i> , 2015 , 126, 4078-4078	2.2	1
146	ASXL1 and CBL Mutations Are Independently Predictive of Inferior Survival in Advanced Systemic Mastocytosis. <i>Blood</i> , 2015 , 126, 828-828	2.2	2
145	Arterial Versus Venous Events in Essential Thrombocythemia and Their Impact on Overall and Thrombosis Free Survival. <i>Blood</i> , 2015 , 126, 1611-1611	2.2	
144	Momelotinib Therapy for Myelofibrosis: Impact on Long-Term Survival and Genotype Correlations. <i>Blood</i> , 2015 , 126, 4062-4062	2.2	
143	Molecular Correlates of Anemia in Primary Myelofibrosis. <i>Blood</i> , 2015 , 126, 4068-4068	2.2	
142	CD123 Immunostaining in Systemic Mastocytosis: Differential Expression in Disease Subgroups and Potential Prognostic Value. <i>Blood</i> , 2015 , 126, 2802-2802	2.2	
141	Survival Trends in Primary Myelodysplastic Syndromes: A Comparative Analysis of 1000 Patients By Year of Diagnosis and Treatment. <i>Blood</i> , 2015 , 126, 2875-2875	2.2	
140	Survival Trends in Essential Thrombocythemia in the Face of Changing Treatment Practices. <i>Blood</i> , 2015 , 126, 2805-2805	2.2	
139	ASXL1 Mutations in Myelodysplastic Syndromes with 1% or More Ring Sideroblasts: Prevalence, Clinical Correlates and Prognostic Relevance. <i>Blood</i> , 2015 , 126, 2882-2882	2.2	
138	Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. <i>American Journal of Hematology</i> , 2014 , 89, E121-4	7.1	145
137	Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. <i>Blood</i> , 2014 , 124, 2507-13; quiz 2615	2.2	424
136	The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. <i>Blood</i> , 2014 , 124, 2465-6	2.2	105
135	In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. <i>Blood</i> , 2014 , 124, 3021-3	2.2	80
134	Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?. <i>Leukemia and Lymphoma</i> , 2014 , 55, 2706-11	1.9	4
133	Drug-drug interaction between bosutinib and warfarin. <i>Leukemia and Lymphoma</i> , 2014 , 55, 2213-4	1.9	3

132	Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2013 , 88, 612-24	7.1	57
131	Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. <i>Blood</i> , 2013 , 122, 1395-8	2.2	218
130	Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis. <i>American Journal of Hematology</i> , 2013 , 88, 312-6	7.1	51
129	How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage). <i>Blood</i> , 2013 , 121, 3085-94	2.2	60
128	International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. <i>Blood</i> , 2013 , 121, 2393-401	2.2	89
127	Effect of the Number of Prognostically Relevant Mutated Genes on Survival and Leukemia Progression in Primary Myelofibrosis. <i>Blood</i> , 2013 , 122, 104-104	2.2	3
126	Update On The Long-Term Efficacy and Safety Of Momelotinib, a JAK1 and JAK2 Inhibitor, For The Treatment Of Myelofibrosis. <i>Blood</i> , 2013 , 122, 108-108	2.2	30
125	Aurora A Kinase Is a Novel Therapeutic Target In The Myeloproliferative Neoplasms. <i>Blood</i> , 2013 , 122, 109-109	2.2	1
124	Clonal Evolution As Determined By Sequential Bone Marrow Karyotype Analysis During JAK Inhibitor Therapy For Myelofibrosis: Impact On Treatment Response and Overall and Leukemia-Free Survival. <i>Blood</i> , 2013 , 122, 2821-2821	2.2	1
123	Chronic Neutrophilic Leukemia With Concurrent CSF3R and SETBP1 Mutations: Single Colony Clonality Studies, In Vitro Sensitivity To JAK Inhibitors and Lack Of Treatment Response To Ruxolitinib. <i>Blood</i> , 2013 , 122, 2830-2830	2.2	1
122	Long-Term Follow Up Of a Randomized Phase II Study Of The JAK2-Selective Inhibitor Fedratinib (SAR302503) In Patients With Myelofibrosis (MF). <i>Blood</i> , 2013 , 122, 4047-4047	2.2	4
121	Retrospective Comparison Of Survival and Leukemic Transformation In Myelofibrosis Patients Treated With Ruxolitinib Versus Momelotinib Versus Fedratinib Versus Pomalidomide. <i>Blood</i> , 2013 , 122, 4049-4049	2.2	1
120	Imetelstat, a Telomerase Inhibitor, Induces Morphologic and Molecular Remissions In Myelofibrosis and Reversal Of Bone Marrow Fibrosis. <i>Blood</i> , 2013 , 122, 662-662	2.2	10
119	BMS-911543, A Selective JAK2 Inhibitor: A Multicenter Phase 1/2a Study In Myelofibrosis. <i>Blood</i> , 2013 , 122, 664-664	2.2	15
118	Normal Karyotype Primary Myelofibrosis (NK-PMF): Clinical and Molecular Prognostication In 690 Patients. <i>Blood</i> , 2013 , 122, 1587-1587	2.2	
117	Serum Ferritin Level At Referral Provides Independent Prognostic Information For Overall Survival In Primary Myelofibrosis. <i>Blood</i> , 2013 , 122, 2824-2824	2.2	
116	U2AF1 mutations In Primary Myelofibrosis Cluster With Normal Karyotype and JAK2V617F and Are Strongly Associated With Anemia and Thrombocytopenia. <i>Blood</i> , 2013 , 122, 4060-4060	2.2	
115	Baseline Spleen Size and Mutations Involving ASXL1 and SRSF2 Predict Survival and Treatment Response In JAK Inhibitor Treated Myelofibrosis Patients. <i>Blood</i> , 2013 , 122, 4048-4048	2.2	

114	Cytogenetic Abnormalities Predict Clinical Outcome In Patients Diagnosed With Relapsed Acute Myeloid Leukemia (rAML): Single Center Experience. <i>Blood</i> , 2013 , 122, 4955-4955	2.2	
113	Management Of PICC-Associated Thrombosis In Patients Receiving Chemotherapy For Hematologic Malignancies. <i>Blood</i> , 2013 , 122, 5000-5000	2.2	
112	Treatment-refractory idiopathic hypereosinophilic syndrome: pitfalls and progress with use of novel drugs. <i>American Journal of Hematology</i> , 2012 , 87, 703-6	7.1	12
111	Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2012 , 87, 401-11	7.1	50
110	One thousand patients with primary myelofibrosis: the mayo clinic experience. <i>Mayo Clinic Proceedings</i> , 2012 , 87, 25-33	6.4	137
109	Systemic mastocytosis: disease overview, pathogenesis, and treatment. <i>Hematology/Oncology Clinics of North America</i> , 2012 , 26, 1117-28	3.1	18
108	Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of Myelofibrosis. <i>Blood</i> , 2012 , 120, 178-178	2.2	7
107	Comprehensive Cytokine Profiling in Systemic Mastocytosis: Prognostic Relevance of Increased Plasma IL-2R Levels.. <i>Blood</i> , 2012 , 120, 2836-2836	2.2	1
106	A Phase II Randomized Dose-Ranging Study of the JAK2-Selective Inhibitor SAR302503 in Patients with Intermediate-2 or High-Risk Primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, or Post-Essential Thrombocythemia (ET) MF.. <i>Blood</i> , 2012 , 120, 2837-2837	2.2	6
105	Decreased Levels of Total or HDL Cholesterol in Primary Myelofibrosis Are Associated with Shortened Survival: DIPSS-Plus Independent Prognostic Value.. <i>Blood</i> , 2012 , 120, 2851-2851	2.2	4
104	Aberrant Megakaryocyte Gene Expression Contributes to Primary Myelofibrosis.. <i>Blood</i> , 2012 , 120, 2867-2867	2.2	2
103	Gene Expression Profiling within the Context of JAK Inhibitor Therapy for Myelofibrosis: Correlation with Treatment Effect and Anemia Response. <i>Blood</i> , 2012 , 120, 1751-1751	2.2	
102	Spliceosome Mutations Involving SRSF2, SF3B1 and U2AF35 in World Health Organization Defined Chronic Myelomonocytic Leukemia; Prevalence, Clinical Correlates and Prognosis. <i>Blood</i> , 2012 , 120, 1711-1711	2.2	
101	Phenotypic and Prognostic Correlates of Spliceosome Mutations (SRSF2, SF3B1, U2AF35) in Chronic Myelomonocytic Leukemia with ≥ 1% Ring Sideroblasts.. <i>Blood</i> , 2012 , 120, 2803-2803	2.2	
100	Survival and Prognosis in World Health Organization Defined Chronic Myelomonocytic Leukemia- A Mayo Clinic Series of 227 Patients. <i>Blood</i> , 2012 , 120, 3790-3790	2.2	
99	Prognostic Interactions Between SRSF2, ASXL1, and IDH Mutations in Primary Myelofibrosis and Determination of Added Value to Cytogenetic Risk Stratification and DIPSS-Plus. <i>Blood</i> , 2012 , 120, 430-430	2.2	
98	Evaluation of IPSS-Revised (IPSS-R) Cytogenetic Risk Stratification and Prognostic Impact of Monosomal Karyotype in 1,014 Patients with Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2012 , 120, 423-423	2.2	
97	Associations and Prognostic Interactions Between Circulating Levels of Hepcidin, Ferritin, and Inflammatory Cytokines in Primary Myelofibrosis.. <i>Blood</i> , 2012 , 120, 2831-2831	2.2	

96	The Effect of Number of Metaphases Studied and Abnormal Metaphase Percentage On Cytogenetic Risk Stratification in Primary Myelofibrosis. <i>Blood</i> , 2012 , 120, 1742-1742	2.2	
95	Risk Factors for Thrombosis Among 1,545 Patients with Polycythemia Vera: An International Study.. <i>Blood</i> , 2012 , 120, 2849-2849	2.2	
94	Neurologic symptoms and diagnosis in adults with mast cell disease. <i>Clinical Neurology and Neurosurgery</i> , 2011 , 113, 570-4	2	28
93	Targeting myeloproliferative neoplasms with JAK inhibitors. <i>Current Opinion in Hematology</i> , 2011 , 18, 105-10	3.3	30
92	Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients. <i>Blood</i> , 2011 , 118, 4595-8	2.2	56
91	Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. <i>Journal of Clinical Oncology</i> , 2011 , 29, 761-70	2.2	589
90	Circulating levels of MCP-1, sIL-2R, IL-15, and IL-8 predict anemia response to pomalidomide therapy in myelofibrosis. <i>American Journal of Hematology</i> , 2011 , 86, 343-5	7.1	16
89	Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2011 , 86, 362-71	7.1	24
88	Infrequent occurrence of MPL exon 10 mutations in polycythemia vera and post-polycythemia vera myelofibrosis. <i>American Journal of Hematology</i> , 2011 , 86, 701-2	7.1	21
87	Vitamin D insufficiency in myeloproliferative neoplasms and myelodysplastic syndromes: clinical correlates and prognostic studies. <i>American Journal of Hematology</i> , 2011 , 86, 1013-6	7.1	21
86	Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. <i>Cancer</i> , 2011 , 117, 4869-4877	6.4	44
85	DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. <i>Journal of Clinical Oncology</i> , 2011 , 29, 392-7	2.2	677
84	Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1356-63	2.2	402
83	Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. <i>Journal of Clinical Oncology</i> , 2011 , 29, 789-96	2.2	328
82	Pomalidomide Therapy for Myelofibrosis: Analysis of Results From Three Consecutive Clinical Trials. <i>Blood</i> , 2011 , 118, 1759-1759	2.2	0
81	Survival and Prognosis Among 1,263 Patients with Polycythemia Vera: An International Study. <i>Blood</i> , 2011 , 118, 277-277	2.2	4
80	SAR302503: Interim Safety, Efficacy and Long-Term Impact on JAK2 V617F Allele Burden in a Phase I/II Study in Patients with Myelofibrosis,. <i>Blood</i> , 2011 , 118, 3838-3838	2.2	8
79	An Expanded Multicenter Phase I/II Study of CYT387, a JAK- 1/2 Inhibitor for the Treatment of Myelofibrosis,. <i>Blood</i> , 2011 , 118, 3849-3849	2.2	10

78	Comprehensive Plasma Cytokine Profiling in Polycythemia Vera: Comparison with Myelofibrosis and Clinical Correlates,. <i>Blood</i> , 2011 , 118, 3850-3850	2.2	1
77	SF3B1 Mutations Are Prevalent in Myelodysplastic Syndromes with Ring Sideroblasts but Do Not Hold Independent Prognostic Value. <i>Blood</i> , 2011 , 118, 460-460	2.2	0
76	Pathogenesis, Diagnosis, Classification, and Management of Systemic Mastocytosis 2011 , 205-221		
75	Predictors of Greater Than 80% Two-Year Mortality in Primary Myelofibrosis: A Mayo Clinic Study of 884 Karyotypically-Annotated Cases. <i>Blood</i> , 2011 , 118, 2806-2806	2.2	
74	IPSS Independent Prognostic Value of Plasma CXCL10, IL-7 and IL-6 Levels in De Novo Myelodysplastic Syndromes,. <i>Blood</i> , 2011 , 118, 3795-3795	2.2	
73	Prognostic Irrelevance of Vitamin D Insufficiency in Myeloproliferative Neoplasms and De Novo Myelodysplastic Syndromes. <i>Blood</i> , 2011 , 118, 5158-5158	2.2	
72	Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis. <i>Blood</i> , 2011 , 118, 1752-1752	2.2	1
71	Leukemia Risk Models in Primary Myelofibrosis: An International Working Group Study,. <i>Blood</i> , 2011 , 118, 3833-3833	2.2	
70	Immunoglobulin Free Light Chain Levels Predict Survival in Primary Myelofibrosis and De Novo Myelodysplastic Syndromes. <i>Blood</i> , 2011 , 118, 1756-1756	2.2	
69	Differential Prognostic Effect of IDH1 Versus IDH2 Mutations in Myelodysplastic Syndromes: A Mayo Clinic Study of 277 Patients. <i>Blood</i> , 2011 , 118, 971-971	2.2	
68	Pruritus in Primary Myelofibrosis: Clinical and Laboratory Correlates. <i>Blood</i> , 2011 , 118, 5154-5154	2.2	
67	CCDC26 Polymorphisms Are Differentially Expressed in Myeloid Malignancies with Mutant IDH1 Compared to Their IDH2R140-Mutated or IDH-Unmutated Counterparts. <i>Blood</i> , 2011 , 118, 2807-2807	2.2	
66	IDH mutations in Primary Myelofibrosis Predict Leukemic Transformation and Shortened Survival: Clinical Evidence for Leukemogenic Collaboration with JAK2V617F. <i>Blood</i> , 2011 , 118, 1751-1751	2.2	
65	LNK mutations in JAK2 mutation-negative erythrocytosis. <i>New England Journal of Medicine</i> , 2010 , 363, 1189-90	59.2	118
64	Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. <i>New England Journal of Medicine</i> , 2010 , 363, 1117-27	59.2	906
63	Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature. <i>Current Opinion in Hematology</i> , 2010 , 17, 125-32	3.3	67
62	WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults. <i>Blood</i> , 2010 , 115, 150-1	2.2	59
61	Proposal for a revised classification of systemic mastocytosis. <i>Blood</i> , 2010 , 115, 2720-1	2.2	15

60	Circulating IL-2R, IL-8, IL-15 and CXCL10 Levels Are Independently Prognostic In Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study. <i>Blood</i> , 2010 , 116, 3068-3068	2.2	1
59	Concomitant Analysis of EZH2 and ASXL1 Mutations In Myelofibrosis, Chronic Myelomonocytic Leukemia and Blast-Phase Myeloproliferative Neoplasms. <i>Blood</i> , 2010 , 116, 3070-3070	2.2	4
58	LNK Mutation Studies In Chronic- and Blast-Phase Myeloproliferative Neoplasms and JAK2 Mutation-Negative Erythrocytosis. <i>Blood</i> , 2010 , 116, 4105-4105	2.2	1
57	Characterization of BMS-911543, a Functionally Selective Small Molecule Inhibitor of JAK2. <i>Blood</i> , 2010 , 116, 4112-4112	2.2	2
56	Longer-Term Follow up with TG101348 Therapy In Myelofibrosis Confirms Sustained Improvement In Splenomegaly, Disease-Related Symptoms, and JAK2V617F Allele Burden. <i>Blood</i> , 2010 , 116, 459-459	2.2	4
55	A Phase I/II Study of CYT387, An Oral JAK-1/2 Inhibitor, In Myelofibrosis: Significant Response Rates In Anemia, Splenomegaly, and Constitutional Symptoms. <i>Blood</i> , 2010 , 116, 460-460	2.2	16
54	Epigenomic Profiling of Myeloproliferative Diseases Reveal Idiopathic Myelofibrosis as An Epigenetically Distinct Subgroup and Highlights the Epigenetic Effects of Jak2V617F Mutation. <i>Blood</i> , 2010 , 116, 627-627	2.2	1
53	DIPSS-Plus: A Refined Dynamic International Prognostic Scoring System (DIPSS) for Primary Myelofibrosis That Incorporates Karyotype, Platelet Count and Transfusion Status. <i>Blood</i> , 2010 , 116, 4104-4104	2.2	1
52	Refined Cytogenetic Risk Categorization for Overall and Leukemia-Free Survival In Primary Myelofibrosis: A Single Center Study of 433 Patients. <i>Blood</i> , 2010 , 116, 4122-4122	2.2	
51	A Phase-2 Trial of Low-Dose Pomalidomide In Myelofibrosis with Anemia. <i>Blood</i> , 2010 , 116, 4109-4109	2.2	1
50	Monosomal Karyotype In Primary Myelofibrosis Is Prognostically Worse Than Otherwise Unfavorable Karyotype. <i>Blood</i> , 2010 , 116, 3069-3069	2.2	
49	Long Term Follow-up and IWG-MRT Response Assessment for 50 Myelofibrosis (MF) Patients Treated with Thalidomide-Prednisone Based Regimens. <i>Blood</i> , 2010 , 116, 4094-4094	2.2	
48	IDH Mutations and Trisomy 8 In Myelodysplastic Syndromes and Acute Myeloid Leukemia. <i>Blood</i> , 2010 , 116, 4009-4009	2.2	
47	Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. <i>American Journal of Hematology</i> , 2009 , 84, 790-4	7.1	135
46	The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. <i>Leukemia Research</i> , 2009 , 33, 1199-203	2.7	173
45	Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. <i>Blood</i> , 2009 , 113, 5727-36	2.2	399
44	Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. <i>Blood</i> , 2009 , 114, 3769-72	2.2	141
43	IPSS-Independent Cytogenetic Risk Categorization in Primary Myelofibrosis.. <i>Blood</i> , 2009 , 114, 2909-2909	2.2	1

42	JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients. <i>Mayo Clinic Proceedings</i> , 2008 , 83, 457-9	6.4	40
41	Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. <i>Clinical Cancer Research</i> , 2008 , 14, 3906-15	12.9	136
40	Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. <i>Blood</i> , 2008 , 111, 2785-9	2.2	115
39	Primary eosinophilic disorders: a concise review. <i>Current Hematologic Malignancy Reports</i> , 2008 , 3, 37-43	4.4	5
38	Characterization of JAK2 V617F Allele Burden in Advanced Myelofibrosis (MF) Patients: No Change in V617F:WT JAK2 Ratio in Patients with High Allele Burdens despite Profound Clinical Improvement Following Treatment with the JAK Inhibitor, INCB018424. <i>Blood</i> , 2008 , 112, 2802-2802	2.2	10
37	The Clinical Phenotype of Myelofibrosis Encompasses a Chronic Inflammatory State That Is Favorably Altered by INCB018424, a Selective Inhibitor of JAK1/2. <i>Blood</i> , 2008 , 112, 2804-2804	2.2	10
36	TG101348, An Orally Bioavailable JAK2-Selective Inhibitor, Potently Inhibits KITD816V and FIP1L1-PDGFR α in Vitro. <i>Blood</i> , 2008 , 112, 2807-2807	2.2	1
35	Prognostically Relevant Breakdown of 138 Patients with Systemic Mastocytosis Associated with Another Hematological Malignancy. <i>Blood</i> , 2008 , 112, 2808-2808	2.2	
34	Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. <i>Cancer</i> , 2007 , 109, 2279-84	6.4	132
33	Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. <i>British Journal of Haematology</i> , 2007 , 138, 354-8	4.5	120
32	Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes. <i>Stem Cells</i> , 2007 , 25, 2358-62	5.8	55
31	Choosing the Right Patients for Clinical Trials in Essential Thrombocythemia or Polycythemia Vera: Leukemic or Fibrotic Transformation Risk Assessment among 1061 Patients from a Single Institution.. <i>Blood</i> , 2007 , 110, 3546-3546	2.2	2
30	INCB018424, an Oral, Selective JAK2 Inhibitor, Shows Significant Clinical Activity in a Phase I/II Study in Patients with Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF).. <i>Blood</i> , 2007 , 110, 558-558	2.2	17
29	Systemic mastocytosis: a concise clinical and laboratory review. <i>Archives of Pathology and Laboratory Medicine</i> , 2007 , 131, 784-91	5	39
28	Erythropoietin Therapy Does Not Benefit Transfusion-Dependent Primary Myelofibrosis Patients and Treatment Response Is Infrequent with a Baseline Hemoglobin Level \geq 10 g/dL.. <i>Blood</i> , 2007 , 110, 3555-3555	2.2	
27	Low JAK2V617F Allele Burden in Primary Myelofibrosis, Compared to Either a Higher Allele Burden or Unmutated Status, Predicts Inferior Overall and Leukemia-Free Survival.. <i>Blood</i> , 2007 , 110, 676-676	2.2	
26	Pruritus in Polycythemia Vera Is More Prevalent in Non-Smokers and Is Independently Associated with a Lower Risk of Arterial Thrombosis.. <i>Blood</i> , 2007 , 110, 2550-2550	2.2	
25	JAK2V617F Mutation Screening as Part of the Hypercoagulable Workup in the Absence of Splanchnic Vein Thrombosis: Assessment of Value in a Series of 664 Consecutive Patients.. <i>Blood</i> , 2007 , 110, 3191-3191	2.2	

24	MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. <i>Blood</i> , 2006 , 108, 3472-6	2.2	833
23	A role for tryptase in myeloid disorders?. <i>Leukemia and Lymphoma</i> , 2006 , 47, 789-90	1.9	1
22	Dysregulated EVI1 expression in myeloid malignancies. <i>Leukemia and Lymphoma</i> , 2006 , 47, 2443-4	1.9	1
21	Discordant distribution of JAK2V617F mutation in siblings with familial myeloproliferative disorders. <i>Blood</i> , 2006 , 107, 4572-3	2.2	25
20	TG101209, a Selective JAK2 Kinase Inhibitor, Suppresses Endogenous and Cytokine-Supported Colony Formation from Hematopoietic Progenitors Carrying JAK2V617F or MPLW515K/L Mutations.. <i>Blood</i> , 2006 , 108, 2680-2680	2.2	3
19	MPLW515L/K and JAK2V617F Mutations: Single Colony Studies, Lineage Restriction, and Chronology of Clonal Emergence.. <i>Blood</i> , 2006 , 108, 116-116	2.2	
18	Single Nucleotide Polymorphism (SNP) Analysis of JAK2 and Relevant Cytokine Receptor Genes in Myeloproliferative Disorders.. <i>Blood</i> , 2006 , 108, 661-661	2.2	
17	Idiopathic Eosinophilia with an Occult T-Cell Clone: Prevalence, FIP1L1-PDGFR A Status, and Clinical Course.. <i>Blood</i> , 2006 , 108, 2701-2701	2.2	
16	Low Incidence of FIP1L1-PDGFR A in Eosinophilic Patients and Long-Term Experience with Imatinib Therapy.. <i>Blood</i> , 2005 , 106, 2590-2590	2.2	
15	Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders. <i>Leukemia Research</i> , 2004 , 28 Suppl 1, S47-52	2.7	22
14	Clinical, genetic, and therapeutic insights into systemic mast cell disease. <i>Current Opinion in Hematology</i> , 2004 , 11, 58-64	3.3	64
13	FIP1L1-PDGFR A fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. <i>Blood</i> , 2004 , 104, 3038-45	2.2	248
12	FIP1L1-PDGFR A and c-kit D816V mutation-based clonality studies in systemic mast cell disease associated with eosinophilia. <i>Haematologica</i> , 2004 , 89, 871-3	6.6	41
11	Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis. <i>Blood</i> , 2003 , 101, 827-30	2.2	54
10	Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. <i>Blood</i> , 2003 , 101, 3391-7	2.2	187
9	CHIC2 deletion, a surrogate for FIP1L1-PDGFR A fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. <i>Blood</i> , 2003 , 102, 3093-6	2.2	327
8	Chronic basophilic leukemia: a distinct clinico-pathologic entity?. <i>European Journal of Haematology</i> , 2003 , 71, 18-22	3.8	22
7	Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease. <i>Leukemia Research</i> , 2003 , 27, 739-42	2.7	38

6	Differential expression of CD2 on neoplastic mast cells in patients with systemic mast cell disease with and without an associated clonal haematological disorder. <i>British Journal of Haematology</i> , 2003 , 120, 691-4	4.5	21
5	Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia. <i>Leukemia Research</i> , 2003 , 27, 883-5	2.7	68
4	2-Chlorodeoxyadenosine therapy for disseminated Langerhans cell histiocytosis. <i>Mayo Clinic Proceedings</i> , 2003 , 78, 301-6	6.4	64
3	Systemic mast cell disease without associated hematologic disorder: a combined retrospective and prospective study. <i>Mayo Clinic Proceedings</i> , 2002 , 77, 1169-75	6.4	30
2	Primer on medical genomics. Part IV: Expression proteomics. <i>Mayo Clinic Proceedings</i> , 2002 , 77, 1185-96	6.4	21
1	Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20 mg twice daily or higher: A real-world experience. <i>British Journal of Haematology</i> ,	4.5	2